China
Ping An, CITIC invest China's Airdoc
Ping An Insurance and CITIC Group have made a Series B investment of undisclosed size in Airdoc, a Chinese medical services company that uses artificial intelligence (AI).
China’s Yimidida raises $266m Series D
Chinese logistics firm Yimidida has raised RMB1.8 billion ($266.1 million) in a Series D round of funding led by Boyu Capital.
US, China-based Apollomics raises $100m Series B
CMB International Capital, a private equity unit of China Merchants Bank, has led a $100 million Series B round for US and China-based biopharmaceutical developer Apollomics.
Chinese cancer database provider Medbanks raises $59m
Beijing and Shanghai-based Medbanks, an information service provider specializing in cancer care, has raised RMB400 million ($59 million) in Series C funding led by CLP Fund.
Sequoia, HighLight lead $80m round for China's BrightGene
Sequoia Capital China and HighLight Capital have led a RMB550 million ($80 million) pre-IPO funding round for BrightGene Bio-Medical Technology, a Chinese developer of innovative and generic drugs. An investment unit of GF Securities also participated.
TPG, CICC establish dual currency China investment platform
TPG Capital and CICC Capital, the private equity arm of China International Capital Corporation (CICC), have agreed to establish a joint platform that will make investments in US dollars and renminbi.
AVCJ Awards 2018: Firm of the Year - Large Cap: Bain Capital
Bain Capital’s recent investment and exit activity underlines the importance of cross-border competencies. The GP also won the awards for Deal of the Year - Large Cap and Exit of the Year - Large Cap
Deal focus: Antengene targets unmet cancer problems
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
China’s Zhiyun Health nets $100m Series C round
Chinese online healthcare services provider Zhiyun Health has raised $100 million in a Series C round of funding across two tranches.
China wearables player Nreal confirms $15m Series A
Nreal, a China-based company that makes advanced virtual reality glasses that resemble normal sunglasses, has raised $15 million in Series A funding from investors including Shunwei Capital.
China's K2VC severs ties with spin-out over IP breach
Chinese early-stage investor China Renaissance K2 Ventures (K2VC) has publicly attacked Next Capital - a spin-out from the venture capital firm - for allegedly stealing confidential information.
Qihoo B2B software spin-out raises $132m
360 Enterprise Security, a Chinese B2B internet security software provider that spun-out from Qihoo 360, has closed a Series B round of funding worth RMB900 million ($132 million), achieving a valuation of RMB20.6 billion.
China Everbright closes global fund at $539m
China Everbright has reached a final close of $539 million on its cross-border investment fund, with the commitments coming from corporate investors, family offices, and fund-of-funds.
China's Miaoshou Doctor raises $72.8m
China-based healthcare care services provider Miaoshou Doctor has raised RMB500 million ($72.8 million) in an extended Series C round of funding led by Starquest Capital, with participation from Sequoia Capital China.
China biotech player Innocare raises $160m
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
SenseTime backs China autonomous driving start-up WeRide
WeRide.ai, a Chinese autonomous driving technology specialist formerly known as Jingchi.ai, has raised several hundred millions of US dollars in an extended Series A round led by local artificial intelligence (AI) company SenseTime.
Shenzhen Capital hits first close on debut M&A fund
Shenzhen Capital Group has reached a first close of RMB1.8 billion ($263 million) on its debut M&A fund. The vehicle has an overall target of RMB3.6 billion.
Chinese gene therapy player raises $45m
New Alliance Capital has led a $45 million Series A round for China-based contract research and manufacturing services provider Thousand Oaks Biopharmaceuticals, with participation by Addor Capital and several other healthcare-focused investors.
CDH leads Series A for Chinese commercial rocket launch player
Chinese commercial rocket developer iSpace has completed an extended Series A round of undisclosed size led by CDH Investments, with participation from Matrix Partners China and local VC Dianke Xinghe.
AVCJ Awards 2018: Operational Value Add: Qingdao Haier
KKR backed in Qingdao Haier at a time when the Chinese white goods giant wanted to expand overseas and address competitive pressure at home. The GP helped it deliver on both fronts
Advantech leads $55m round for China biotech player
Advantech Capital has led a $55 million Series B funding round for China’s Connect Biopharmaceuticals with support from Qiming Venture Partners.
Lightspeed China closes US dollar fund at $560m
Lightspeed China Partners has closed its latest US dollar-denominated fund at $560 million. It is the largest fund raised by the firm to date and brings assets under management to $1.5 billion.
China’s Antengene raises $120m Series B round
Antengene Corporation, a Chinese biopharmaceutical company focused on oncology drugs and therapies, has raised $120 million in a Series B round led by Boyu Capital and FountainVest Partners.
Sequoia-backed Futu Securities files for US IPO
Futu Securities International, a Hong Kong-based online brokerage backed by Sequoia Capital China and Matrix Partners China, has filed to list in the US.